



BAIN & COMPANY

Promise and Reality of Personalized Medicine 2011

Keynote Speech at the Bio Deutschland Business Development Conference Hamburg, July 21, 2011

Disclaimer

- This Report may not be copied or provided, in whole or in part, to any third party without the explicit prior written permission of Bain.
- This work is based on secondary market research, analysis of financial or operational information available or provided to Bain, and a range of interviews with customers, competitors and industry experts, and relevant Bain experience. Bain has not independently verified any such information and makes no representation or warranty, express or implied, that such information is accurate or complete. Projected data and conclusions contained herein are based (unless sourced otherwise) on the information described above and Bain's best judgment and should not be construed as definitive forecasts. Bain does not have any duty to update or supplement any information in the Report.
- No responsibility or liability whatsoever is accepted by any person including Bain & Company, Inc. or its affiliates and their respective officers, employees or agents for any errors or omissions in this Report, save insofar as Bain may expressly agree in writing.
- This Report is not complete without an accompanying oral discussion and presentation by Bain.

So far, advances in PM have not materialized at the pace originally expected

1990 2000 2005 2010 1995 HGP: "The HGP: "In two or (BMC) Ardeshir Ohio Health 2007: Investorplace 2011: information three decades, we Bayat 2002: "Patients "A promising "Double-digit growth generated by the hope to be able to will carry gene cards approach to predicted during the Expechuman genome find out what genetic with their own transform the next several years project is expected disease a person is unique genetic healthcare system is for MDx, the market tations to be the source at risk for and fix it profile for certain to develop and is expected to reach for book for biomedical \$8-billion worldwide by putting in a gene drugs aimed at implement near that has the personalized health by 2015" science in the 21st individualized century and will be appropriate therapy and targeted care." future of immense benefit sequence" medicine free from to the field of side effects." medicine" Human Genome ~250 gene-derived
HGP announced • 9th human geno- Few PHC products Project initiated, products in clinical draft. Overall me completely in market: project planned for development, sequence declared sequenced in Herceptin, 2008. However, so 15 years public property Glivec, Erbitux, • 100 companies far no clear Tarceva and Reality currently have Herceptin admisconclusions from **Sprvcel** exceed \$ **DNA-based** sion for metast. genetic risk profile 1 B yearly therapies in breast cancer possible revenue. human clinical treatment (US: trials 1998, EU: 2000) 2003 Glivec approved in EU Antisense hits roadblock

All stakeholders continue to find PM business model challenging

Challenges for successful launch of PM drug

Pharma and Dx

Regulator

Payer

Provider/ GP

Rx

- Understanding of commercial requirements for the combination of drug and diagnostic
- Insufficient link to reduced development cost
- Early trade-off vs. maximizing patient population

- Large differences in Rx and Dx economics and timelines
- Few business models with profitable revenue

Dx

- Limited experience with clinical development and regulatory affairs across pharma and Dx
- Dx IP offers less protection than composition of matter


- Uncertainty around regulatory requirements for Dx (e.g., prospective vs. retrospective inclusion)
- Regional differences in regulatory guidance e.g., KRAS
- Limited Dx regulatory capabilities

- Economics of Dx test as such (e.g., Coumadin)
- Limited reimbursement of Dx
- Extended duration required to collect longitudinal evidence

- Limited physician awareness
- Unclear benefit of new treatment algorithm for practice economics
- Complexity of marketing & sales approaches that combine Rx and Dx


Fundamentally different Rx Co & Dx Co economics & timelines imply tradeoffs

CONCEPTUAL



^{*}ROCE includes Top 3 Dx Cos and excludes Roche Diagnostics Source: Literature search; Company websites; Company Annual Reports; Company 10-Ks; Bloomberg; Bain Analysis


Even though not as fast as expected, PM-related revenues have grown significantly



Note: Tarceva not included given EGFR test not required by label (despite being listed in genomics@FDA table) Source: EvaluatePharma, Team analysis

PM drugs with companion diagnostics represent increasing share of drug spend in top 7 markets

Market share of PM drugs with companion diagnostic*




^{*}Revenues for USA, EU5 and Japan; Source: EvaluatePharma, PharmaVitaeMonitor

Over time, penetration of PM is set to increase by volume and value

INDICATIVE


Share of PM enabled drugs (in % of total)



Note: * per previous definitions -Top 7 (former top 10 after mergers) Pharma companies applying PM and against top 7 revenues; ** Share of trials of top 7 (former top 10) PM players

Early phase PM enabled research covering few large therapeutic areas, further TAs to follow

PM-enabled PIII/PIV and PI/PII trials 2010 (in % of total)




Note: Infectious disease excludes HIV trials

PM-enabled indicates the active use of biomarkers as part of the clinical trial, and includes use in patient selection, and disease selection

Source: ClinicalTrials.gov, Bain analysis

Over time more MDx expected in labels, modern methods growing slowly




Source: clinicaltrials.gov , Bain analysis

WET

SEQ

Players in MDx segment execute different underlying business models



Note: Smaller, focused providers often develop disease-linked diagnostics for use in clinical trials, with limited regulatory submission Source: Literature search; Company websites; Company Annual Reports; Company 10-Ks

Successful MDx businesses shaping around specialized players with distinct characteristics

Niche player

approval



Focused player



Platform player



Product / technology

Regulatory

approval /

reimburse-

ment

2 Oncotype Dx prognostics test to guide breast and colon cancer risk assessment and treatment selection

studies to accelerate

- Clinical-economical
- adoption, but lacks FDA
- Reimbursed by Medicare and major managed care organizations in the US
- Included in ASCO/NCCN guidelines

- Cancer diagnostics portfolio incl. reagents and instruments with primary focus on Immunohistochemistry
- Multiple test kits with FDA approval including HER2, TOP2A and EGFR as target
- Various products with reimbursement from public authorities

- Proprietary diagnostics technologies and services with focus on ID across broad range of TAs
- Only FDA-approved blood-screening assay for simultaneous detection of HIV-1 and Hepatitis C Virus

Kev collaborations and acquisitions

- Exclusive agreements with Medical Solutions (UK) and Palex Medical S.A. (Spain, Portugal)
- Collaboration with Pfizer for renal cell carcinoma prognostic test
- Framework agreement with AZ on the development of companion Dx
- Various other pharma partnerships e.g., with Genentech and BMS
- Acquired Tepnel Life Sciences plc (April 2009) and Prodesse, Inc. (December 2009)

For Rx (Pharma) possible strategic options vary depending on skills & assets already owned

High

Differentiated Gx players:

"become a solutions provider to the economic buyer"

- Combine broad drug portfolio with Dx to provide attractive, integrated solutions to payer decision makers
- Ensure access to relevant IP and combined offerings

Pharma front-runners in PM:

"change the game in my favor"

- Driving PM forward by identifying possible tipping point s early and securing access to critical IP
- Broaden PM outside of Oncology and ID to maximize returns on early investments

Standard Gx player:

"not applicable"

- Continue to manage cost along the experience / scale curve
- Do not increase complexity

Most pharma players:

"buck the trend at reasonable investment levels"

- Continue through partnering (Dx JVs and partnerships) to cover own core PM exposure
- Invest as appropriate to ensure Dx availability at critical junctures

Low

Low

High

Exposure to personalized medicine

Personalized Medicine - Promise and Realities 2011

- "The Promise" continues to be there and remains significant
- Reality looks different than we thought it would, but gradually sets in
 - -4% penetration today
 - -20%+ on horizon
- Continued success in this field requires
 - -Better understanding of business models and opportunities between Rx and Dx
 - -Clear strategic choices supported by early and sometimes audacious investments in capabilities and new technologies